Analysis of plasma biomarkers from PTCL patients showed a decrease in CD30 levels from baseline to Cycle 3 Day 1 and this correlated with response seen in these patients. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.